{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:29:31Z","timestamp":1787030971413,"version":"build-2736575974"},"reference-count":16,"publisher":"Scientific Scholar","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"\n Background & objectives:<\/jats:title>\n The World Health Organisation recommended immediate initiation of antiretroviral therapy (ART) in all adult human immunodeficiency virus (HIV) patients regardless of their CD4 cell count. This study was undertaken to ascertain the cost-effectiveness of implementation of these guidelines in India.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n A Markov model was developed to assess the lifetime costs and health outcomes of three scenarios for initiation of ART treatment at varying CD4 cell count <350\/mm\n 3<\/jats:sup>\n , <500\/mm\n 3<\/jats:sup>\n and test and treat using health system perspective using life-time horizon. A few input parameters for this model namely, transition probabilities from one stage to another stage of HIV and incidence rates of TB were calculated from the data of Centre of Excellence for HIV treatment and care, Chandigarh; whereas, other parameters were obtained from the published literature. Total HIV-related deaths averted, HIV infections averted and incremental cost-effectiveness ratio per quality adjusted life years (QALYs) gained were calculated.\n <\/jats:p>\n <\/jats:sec>\n \n Result:<\/jats:title>\n \n Test and treat intervention slowed down the progression of disease and averted 18,386 HIV-related deaths, over lifetime horizon. It also averted 16,105 new HIV infections and saved 343,172 QALYs as compared to the strategy of starting ART at CD4 cell count of 500\/mm\n 3<\/jats:sup>\n . Incremental cost per QALY gained for the immediate initiation of ART as compared to ART at CD4 cell count of 500\/mm\n 3<\/jats:sup>\n and 350\/mm\n 3<\/jats:sup>\n was\n <\/jats:p>\n JOURNAL\/ijmer\/04.03\/02223309-202212000-00002\/math_2MM1\/v\/2023-05-19T183840Z\/r\/image-tiff<\/jats:p>\n 46,599 and 80,050, respectively at reported rates of adherence to the therapy.<\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions:<\/jats:title>\n Immediate ART (test and treat) is highly cost-effective strategy over the past criteria of delayed therapy in India. Cost-effectiveness of this policy is largely because of reduction in the transmission of HIV.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_806_20","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T02:35:28Z","timestamp":1681094128000},"page":"705-714","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness analysis of \u2018test and treat\u2019 policy for antiretroviral therapy among heterosexual HIV population in India"],"prefix":"10.25259","volume":"156","author":[{"given":"Malkeet","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Bahuguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Jyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Prinja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R3-2-20241212","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4103\/2224-3151.206171","article-title":"Adoption of the 2015 World Health Organization guidelines on antiretroviral therapy: Programmatic implications for India","volume":"6","author":"Rewari","year":"2017","journal-title":"WHO South East Asia J Public Health"},{"key":"R4-2-20241212","doi-asserted-by":"crossref","first-page":"e000259","DOI":"10.1136\/bmjgh-2016-000259","article-title":"Institutionalising health technology assessment: Establishing the Medical Technology Assessment Board in India","volume":"2","author":"Downey","year":"2017","journal-title":"BMJ Glob Health"},{"key":"R5-2-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s41669-017-0037-0","article-title":"Health technology assessment for policy making in India: Current scenario and way forward","volume":"2","author":"Prinja","year":"2018","journal-title":"Pharmacoecon Open"},{"key":"R7-2-20241212","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1086\/522546","article-title":"Cost-effectiveness of HIV testing and treatment in the United States","volume":"45","author":"Walensky","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R8-2-20241212","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2214-109X(21)00034-6","article-title":"Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial","volume":"9","author":"Thomas","year":"2021","journal-title":"The Lancet Global Health"},{"key":"R10-2-20241212","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2214-109X(13)70172-4","article-title":"Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models","volume":"2","author":"Eaton","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R11-2-20241212","doi-asserted-by":"crossref","first-page":"20217","DOI":"10.7448\/IAS.18.1.20217","article-title":"Economic and epidemiological impact of early antiretroviral therapy initiation in India","volume":"18","author":"Maddali","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"R12-2-20241212","first-page":"903","article-title":"Assessment of clinico-immunological profile of newly diagnosed HIV patients presenting to a teaching hospital of eastern India","volume":"139","author":"Bishnu","year":"2014","journal-title":"Indian J Med Res"},{"key":"R13-2-20241212","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1310\/hct0904-225","article-title":"Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States","volume":"9","author":"Simpson","year":"2008","journal-title":"HIV Clin Trials"},{"key":"R14-2-20241212","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"R15-2-20241212","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/0956462419839852","article-title":"Cost of antiretroviral treatment for HIV patients in two centres of North India","volume":"30","author":"Sharma","year":"2019","journal-title":"Int J STD AIDS"},{"key":"R16-2-20241212","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1472-6963-5-69","article-title":"Cost and efficiency of public sector sexually transmitted infection clinics in Andhra Pradesh, India","volume":"5","author":"Dandona","year":"2005","journal-title":"BMC Health Serv Res"},{"key":"R17-2-20241212","first-page":"12","article-title":"Estimating provider cost for treating patients with tuberculosis under Revised National Tuberculosis Control Programme (RNTCP)","volume":"53","author":"Muniyandi","year":"2006","journal-title":"Indian J Tuberc"},{"key":"R19-2-20241212","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1086\/649884","article-title":"Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India","volume":"50","author":"Bender","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R20-2-20241212","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40258-021-00668-y","article-title":"National methodological guidelines to conduct budget impact analysis for health technology assessment in India","volume":"19","author":"Prinja","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"R23-2-20241212","first-page":"84","article-title":"Level of suboptimal adherence to first line antiretroviral treatment & its determinants among HIV positive people in India","volume":"140","author":"Joshi","year":"2014","journal-title":"Indian J Med Res"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.IJMR_806_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:05:40Z","timestamp":1751483140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/cost-effectiveness-analysis-of-test-and-treat-policy-for-antiretroviral-therapy-among-heterosexual-hiv-population-in-india\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_806_20","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}